Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
The salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infect...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4214720?pdf=render |
id |
doaj-5fa51311598a47578bc6f308764c4d7d |
---|---|
record_format |
Article |
spelling |
doaj-5fa51311598a47578bc6f308764c4d7d2020-11-25T01:43:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e11091810.1371/journal.pone.0110918Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.Christian PedersenAnatoly SlepenkinSara B E AnderssonJonas H FagerbergChristel A S BergströmEllena M PetersonThe salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infection the SA compound INP0341, when dissolved in a liquid, was able to significantly protect mice from a vaginal infection with C. trachomatis. To expand upon this finding, in this report INP0341 was formulated as a vaginal gel, suitable for use in humans. Gelling agents (polymers) with inherent antimicrobial properties were chosen to maximize the total antimicrobial effect of the gel. In vitro formulation work generated a gel with suitable rheology and sustained drug release. A formulation containing 1 mM INP0341, 1.6 wt% Cremophor ELP (solubility enhancer) and 1.5 wt% poly(acrylic acid) (gelling and antimicrobial agent), was chosen for studies of efficacy and toxicity using a mouse model of a vaginal infection. The gel formulation was able to attenuate a vaginal challenge with C. trachomatis, serovar D. Formulations with and without INP0341 afforded protection, but the inclusion of INP0341 increased the protection. Mouse vaginal tissue treated with the formulation showed no indication of gel toxicity. The lack of toxicity was confirmed by in vitro assays using EpiVaginal tissues, which showed that a 24 h exposure to the gel formulation did not decrease the cell viability or the barrier function of the tissue. Therefore, the gel formulation described here appears to be a promising vaginal microbicide to prevent a C. trachomatis infection with the potential to be expanded to other sexually transmitted diseases.http://europepmc.org/articles/PMC4214720?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christian Pedersen Anatoly Slepenkin Sara B E Andersson Jonas H Fagerberg Christel A S Bergström Ellena M Peterson |
spellingShingle |
Christian Pedersen Anatoly Slepenkin Sara B E Andersson Jonas H Fagerberg Christel A S Bergström Ellena M Peterson Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. PLoS ONE |
author_facet |
Christian Pedersen Anatoly Slepenkin Sara B E Andersson Jonas H Fagerberg Christel A S Bergström Ellena M Peterson |
author_sort |
Christian Pedersen |
title |
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. |
title_short |
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. |
title_full |
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. |
title_fullStr |
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. |
title_full_unstemmed |
Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. |
title_sort |
formulation of the microbicide inp0341 for in vivo protection against a vaginal challenge by chlamydia trachomatis. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
The salicylidene acylhydrazide (SA) compounds have exhibited promising microbicidal properties. Previous reports have shown the SA compounds, using cell cultures, to exhibit activity against Chlamydia trachomatis, herpes simplex virus and HIV-1. In addition, using an animal model of a vaginal infection the SA compound INP0341, when dissolved in a liquid, was able to significantly protect mice from a vaginal infection with C. trachomatis. To expand upon this finding, in this report INP0341 was formulated as a vaginal gel, suitable for use in humans. Gelling agents (polymers) with inherent antimicrobial properties were chosen to maximize the total antimicrobial effect of the gel. In vitro formulation work generated a gel with suitable rheology and sustained drug release. A formulation containing 1 mM INP0341, 1.6 wt% Cremophor ELP (solubility enhancer) and 1.5 wt% poly(acrylic acid) (gelling and antimicrobial agent), was chosen for studies of efficacy and toxicity using a mouse model of a vaginal infection. The gel formulation was able to attenuate a vaginal challenge with C. trachomatis, serovar D. Formulations with and without INP0341 afforded protection, but the inclusion of INP0341 increased the protection. Mouse vaginal tissue treated with the formulation showed no indication of gel toxicity. The lack of toxicity was confirmed by in vitro assays using EpiVaginal tissues, which showed that a 24 h exposure to the gel formulation did not decrease the cell viability or the barrier function of the tissue. Therefore, the gel formulation described here appears to be a promising vaginal microbicide to prevent a C. trachomatis infection with the potential to be expanded to other sexually transmitted diseases. |
url |
http://europepmc.org/articles/PMC4214720?pdf=render |
work_keys_str_mv |
AT christianpedersen formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis AT anatolyslepenkin formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis AT sarabeandersson formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis AT jonashfagerberg formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis AT christelasbergstrom formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis AT ellenampeterson formulationofthemicrobicideinp0341forinvivoprotectionagainstavaginalchallengebychlamydiatrachomatis |
_version_ |
1725033311053545472 |